India markets close in 2 hours 14 minutes

CanSino Biologics Inc. (6185.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
355.200-14.600 (-3.95%)
As of 3:31PM HKT. Market open.
Full screen
Previous close369.800
Open363.000
Bid355.200 x 0
Ask357.000 x 0
Day's range350.200 - 374.600
52-week range141.100 - 449.600
Volume1,614,276
Avg. volume1,498,476
Market cap135.039B
Beta (5Y monthly)-0.75
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • COVID vaccines mint new billionaires as BioNTech and Moderna CEOs' wealth soars
    Yahoo Finance UK

    COVID vaccines mint new billionaires as BioNTech and Moderna CEOs' wealth soars

    While the coronavirus pandemic has plunged global economies into recession, plummeted stock markets, it has also captured a snapshot of the impact of the crisis on the wealthy.

  • CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial
    Reuters

    CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial

    Mexico has received the first doses of a COVID-19 vaccine candidate from Chinese pharmaceutical company CanSino Biologics Inc. for a late stage-trial on between 10,000 and 15,000 volunteers, foreign minister Marcelo Ebrard said on Tuesday. The country aims to vaccinate nearly all of its population against COVID-19 by the end of 2021 after reaching accords with pharmaceutical companies and the World Health Organization-backed COVAX plan. "On October 30, the first doses were received to carry out phase three of clinical trials of the candidate vaccine from Cansino Bio," Ebrard said at a news conference, adding that it would be one of the world's largest COVID-19 clinical trials.

  • CanSino Phase 3 COVID-19 vaccine trial in Pakistan expected to begin this month
    Reuters

    CanSino Phase 3 COVID-19 vaccine trial in Pakistan expected to begin this month

    Falling COVID-19 infection numbers in Pakistan will not affect a Phase 3 clinical trial for a potential vaccine being developed by China's CanSino Biologics, which is expected to begin this month, according to officials running the trial. Pakistan’s drug regulator last month gave the go-ahead for the country’s first Phase 3 clinical trial for CanSino's candidate, Ad5-nCoV, which will be led by the government-run National Institute of Health (NIH) along with pharmaceutical company AJM - the local representative of CanSino.